J&J to Improve Drug-Marketing Oversight to Settle Lawsuits
This article is for subscribers only.
Johnson & Johnson, the world’s biggest health-products maker, will provide more corporate oversight of its units’ drug manufacturing and marketing practices to resolve investor lawsuits alleging directors ignored wrongdoing, according to court filings today.
J&J officials agreed to create a board-level group to oversee subsidiaries’ compliance with regulatory rules and to adopt updated risk-management policies as part of the settlement of claims filed against directors in federal court in Trenton, New Jersey.